gadofosveset trisodium
Trade name: ablavar
Small moleculeapproved
Approved
Dec 22, 2008
Gadofosveset is a gadolinium-based MRI contrast agent. It was used as the trisodium salt monohydrate form. It acts as a blood pool agent by binding to human serum albumin. The manufacturer discontinued production in 2017 due to poor sales. — Wikipedia
Clinical trial activity
10 trials · 10 clinical orgs · 2 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
3
Earliest trial started Feb 1, 2006 (NCT00296855)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 3 Sponsor(trial)
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
- Dec 22, 2008
Epix Pharmaceuticals — Earliest FDA Approval
- Dec 22, 2008
Lantheus Medical Imaging — NDA Secondary Org
- Dec 22, 2008
Epix Pharmaceuticals — NDA Organization
2010s
- Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Serum albuminBINDING AGENT
ALB binding agent
- Unspecified targetOTHER
Diagnostic agent
Approval history
- approvedDec 22, 2008
Chemistry & pharmacology
- Mol. weight
- 957.87 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Black box warning
Sources
- WikipediaGadofosveset ↗
- ChEMBLCHEMBL1908843 ↗
- ChEMBLCHEMBL1908362 ↗
Also known as
- ablavar
- ablavar
- ablavar
- gadofosveset
- gadofosveset
- gadofosveset
- gadofosveset
- gadofosveset
- gadofosveset
- gadofosveset trisodium
- gadofosveset trisodium
- gadofosveset trisodium
- gadofosveset trisodium
- gadofosveset trisodium
- gadofosveset trisodium
- gadofosveset trisodium
- gadofosveset trisodium
- gadofosveset trisodium
- gadofoveset
- ms 325
- ms-325
- ms-32520
- ms-32520
- vasovist
- vasovist
- vasovist
- vasovist
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02752191 | Phase 4 | Apr 1, 2016 | University of California, Los Angeles |
| NCT02243059 | Phase 4 | Sep 1, 2014 | Maastricht University |
| NCT01655043 | Phase 2 | Sep 1, 2012 | Astellas, Northwestern University |
| NCT01609920 | N/A | May 1, 2012 | Maastricht University |
| NCT01437865 | N/A | Sep 1, 2011 | Maastricht University |
| NCT01431300 | N/A | Aug 1, 2011 | Duke University, Lantheus Medical Imaging |
| NCT00459446 | Phase 1 | Apr 5, 2007 | National Heart, Lung, and Blood Institute (NHLBI) |
| NCT00668824 | Phase 4 | Mar 1, 2007 | University of London |
| NCT00415805 | Phase 3 | Dec 1, 2006 | Bracco |
| NCT00296855 | Phase 3 | Feb 1, 2006 | Bayer |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Maastricht University | Academic/Hospital | 3 | 3 | 2 | 2011 |
| Astellas | For profit | 1 | 0 | 1 | 2012 |
| Bayer | For profit | 1 | 1 | 1 | 2006 |
| Bracco | For profit | 1 | 1 | 1 | 2006 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Lantheus Medical Imaging | For profit | 1 | 0 | 1 | 2011 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 1 | 1 | 2007 |
| Northwestern University | Academic/Hospital | 1 | 1 | 1 | 2012 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2007 |
10 organizations
Page 1 / 1
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Epix Pharmaceuticals | For profit | NDA | Dec 22, 2008 |
| Lantheus Medical Imaging | For profit | NDA2 | Dec 22, 2008 |